Searched for
LUPIN APIS
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Lupin enters CDMO business, names Abdelaziz Toumi as CEO of new subsidiaryLupin, a pharmaceutical company, has launched a new subsidiary named Lupin Manufacturing Solutions (LMS) to enter the Contract Development ...
- Lupin appoints Abdelaziz Toumi as CEO of newly formed armLupin Ltd appointed Abdelaziz Toumi as CEO of its new subsidiary, Lupin Manufacturing Solutions (LMS). Toumi, with over 20 years in biotech...
- Fundamental Radar: Why risk-reward in Lupin remains favourable even after 80% run-up?The company’s US business was adversely impacted by regulatory issues. However, with clearance for the formulation sites, the product pipel...
- Buy Lupin, target price Rs 1200: Axis SecuritiesPromoters held 47.07 per cent stake in the company as of 30-Jun-2023, while FIIs owned 13.93 per cent, DIIs 28.94 per cent.
- Lupin gets tentative USFDA nod for Dolutegravir, Emtricitabine and Tenofovir Alafenamide tabletsThe tentative approval by the United States Food and Drug Administration (USFDA) has been granted under the President's emergency plan for ...
- Lupin gets USFDA nod for HIV drug under PEPFARLupin got a green signal from the US health regulator to sell HIV drug in the American market. The product that has received a nod under US...
- Lupin gets 5 observations from USFDA for its Vizag facilityThe inspection of company's Vizag API manufacturing facility by the United States Food and Drug Administration (USFDA) has been completed, ...
- USFDA makes 22 observations post inspection of Lupin's Mandideep facilitiesLupin said the observations are "largely procedural in nature with some gaps identified in the aseptic processing areas of the Cephalospori...
- The new USFDA commissioner actually knows his job: Amit Rajan, Director, Celogen Life SciencesData integrity per se will not be an issue for big Indian pharma companies: Amit Rajan, Director, Celogen Life Sciences.
- Lupin launches generic drug to treat depression in USLupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded and generic formulations,...
- Buy Lupin Ltd., target Rs 1831.0 : Karvy Stock Broking LtdKarvy Stock Broking has upgraded Lupin's EPS estimates by 6.3% for FY17 and 2.3% for FY18.
- Lupin launches generic oral contraceptive tablets in USThe USFDA had earlier given approval to market a generic version of Janssen Pharmaceuticals, Inc.'s Ortho Tri-Cyclen tablets in the same st...
- Lupin aims to break into top 5 in Japanese marketDrug maker Lupin today said it is aiming to become one of the top five generic pharmaceutical companies in Japan in the next three years.
- Ranbaxy ban to help Chinese companiesUS Food and Drug Administration’s ban on seven API products of Ranbaxy may turn out to be a boon for the company’s Chinese peers, according...
- Lupin acquires pharma business of RubaminDrug maker Lupin Ltd on Thursday said it has acquired the pharmaceutical business of Rubamin group, for an undisclosed amount.
- Lupin Q4 profit soars to Rs 137 crDrugmaker Lupin on Wednesday reported close to three-fold growth in net profit to Rs 137.08 crore for the three months ended March 31, 2007...
- Lupin proposes to set up a SEZ in MaharashtraPharma major Lupin proposes to set up a sector-specific Special Economic Zone (SEZ) in Maharashtra to produce API and formulations with an ...
Load More
